Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations Journal Article


Authors: Lin, R. J.; Ho, C.; Hilden, P. D.; Barker, J. N.; Giralt, S. A.; Hamlin, P. A.; Jakubowski, A. A.; Castro-Malaspina, H. R.; Robinson, K. S.; Papadopoulos, E. B.; Perales, M. A.; Sauter, C. S.
Article Title: Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations
Abstract: TP53 alterations portend extremely poor prognosis in patients with mantle cell lymphoma treated with standard treatment modalities. We reviewed outcomes of 42 patients with available TP53 status who had received a reduced-intensity or non-myeloablative allogeneic haematopoietic cell transplant at our institution. We demonstrated a 2-year overall survival and progression-free survival of 78% [95% confidence interval (CI) 60–88] and 61% (95% CI 43–75), respectively. The 2-year cumulative incidences of relapse and non-relapse mortality were 19% and 20%, respectively. Importantly, there is no significant difference among patients with and without TP53 alterations, suggesting for the first time a beneficial treatment modality for these high-risk patients. © 2018 British Society for Haematology and John Wiley & Sons Ltd
Keywords: mantle cell lymphoma; tp53; allogeneic hematopoietic cell transplant
Journal Title: British Journal of Haematology
Volume: 184
Issue: 6
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2019-03-11
Start Page: 1006
End Page: 1010
Language: English
DOI: 10.1111/bjh.15721
PUBMED: 30537212
PROVIDER: scopus
PMCID: PMC6399037
DOI/URL:
Notes: Article -- Export Date: 1 April 2019 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Sergio Andres Giralt
    535 Giralt
  2. Craig Steven Sauter
    166 Sauter
  3. Miguel-Angel Perales
    378 Perales
  4. Juliet N Barker
    227 Barker
  5. Paul Hamlin
    173 Hamlin
  6. Patrick Dale Hilden
    85 Hilden
  7. Caleb   Ho
    22 Ho
  8. Richard Jirui Lin
    9 Lin